Medical School · Year 2 · Endocrine · includes a quiz and discussion video

Lecture 14: Endocrine Pharmacology

Unit 2.3: Endocrine System

Learning Objectives

By the end of this lecture, students will be able to:

1. Describe the pharmacology of thyroid and antithyroid drugs
2. Explain adrenal pharmacology including glucocorticoids and mineralocorticoids
3. Describe drugs affecting calcium and bone metabolism
4. Explain pituitary hormone analogs and antagonists
5. Describe the pharmacology of agents used in reproductive endocrinology
6. Explain drug interactions and adverse effects in endocrine pharmacotherapy

Lecture Outline

I. Thyroid Pharmacology - Thyroid Hormone Replacement

Thyroid hormone replacement is one of the most commonly prescribed therapies in endocrinology, with levothyroxine ranking among the top medications by prescription volume worldwide. Understanding the pharmacokinetic properties of thyroid hormone preparations, the factors that affect their absorption and metabolism, and the nuances of dosing in special populations is essential for effective management of hypothyroidism and related conditions.

Levothyroxine (T4) is the standard of care for thyroid hormone replacement. As a synthetic form of thyroxine, it is converted to the biologically active triiodothyronine (T3) by tissue deiodinases, thereby providing a physiologic ratio of T4 to T3. Its indications include treatment of hypothyroidism from any cause and TSH suppression in patients with thyroid cancer. The full replacement dose for levothyroxine is approximately 1.6 micrograms per kilogram per day, though the actual dose is titrated based on TSH levels measured 6 to 8 weeks after any dose change. Administration should occur on an empty stomach with consistent timing each day to ensure reliable absorption. The long half-life of approximately 7 days provides stable serum levels with once-daily dosing and allows for flexibility if an occasional dose is missed.

Several factors significantly influence levothyroxine absorption and metabolism, requiring careful attention. Food decreases absorption and should be avoided for 30 to 60 minutes after taking the medication. Calcium supplements, iron preparations, and antacids bind levothyroxine in the gastrointestinal tract and must be separated by at least 4 hours. Proton pump inhibitors may decrease absorption by altering gastric pH. In pregnancy, levothyroxine requirements typically increase by 25 to 30% early in gestation due to increased thyroxine-binding globulin (TBG) production stimulated by estrogen, expanded plasma volume, and placental metabolism of thyroid hormone; TSH should be monitored frequently during pregnancy and dose adjustments made promptly. In elderly patients and those with coronary artery disease, levothyroxine should be initiated at a low dose (25 to 50 micrograms) and titrated slowly, as rapid restoration of euthyroidism can precipitate angina, arrhythmias, or myocardial infarction by increasing myocardial oxygen demand.

Liothyronine (T3) is a synthetic form of triiodothyronine that has a much faster onset and shorter duration than levothyroxine, with a half-life of approximately 1 day compared to 7 days for T4. Its primary indication is in the acute setting of myxedema coma, where it is used in combination with levothyroxine to rapidly restore thyroid hormone levels. However, liothyronine is generally not recommended for routine thyroid hormone replacement because its short half-life produces variable serum levels with peaks and troughs throughout the day, and it is associated with more cardiac side effects due to these fluctuations. Some practitioners have explored combination T4/T3 therapy based on the rationale that a subset of patients may have impaired T4-to-T3 conversion, though the evidence does not demonstrate clear benefit of combination therapy over T4 monotherapy. Accordingly, levothyroxine monotherapy remains the standard recommendation for the vast majority of patients requiring thyroid hormone replacement.

<image>Panel A: Levothyroxine (T4) overview showing synthetic T4 converted to T3 in tissues, full replacement dose of 1.6 mcg/kg/day, empty stomach administration with consistent timing, and 7-day half-life allowing once-daily dosing. Panel B: Levothyroxine drug interactions and absorption factors showing food decreasing absorption, calcium and iron requiring 4-hour separation, PPIs potentially decreasing absorption, and TSH-based dose titration. Panel C: Special populations showing pregnancy (increase dose 25-30% early), elderly or CAD patients (start low at 25-50 mcg and titrate slowly), and TSH suppression dosing for thyroid cancer. Panel D: Liothyronine (T3) and combination therapy showing T3 indications limited to myxedema coma (with T4), more potent but shorter half-life (1 day) with variable levels and more cardiac effects, and T4 monotherapy remaining the standard recommendation over combination T4/T3.</image>

II. Antithyroid Drugs

The pharmacologic management of hyperthyroidism employs several classes of agents that target different steps in thyroid hormone synthesis, release, and peripheral metabolism. Thionamides are the primary antithyroid medications, while radioactive iodine provides a definitive ablative approach. Understanding the nuances of drug selection, side effect profiles, and specific clinical situations requiring particular agents is essential for safe and effective treatment.

The thionamides—methimazole (MMI) and propylthiouracil (PTU)—are the mainstay of antithyroid drug therapy. Both agents inhibit thyroid peroxidase (TPO), the enzyme responsible for organification of iodide and coupling of iodotyrosines, thereby blocking the synthesis of new thyroid hormone. PTU has an additional mechanism not shared by methimazole: it inhibits the peripheral conversion of T4 to T3 by blocking the type 1 deiodinase enzyme, an effect that is particularly valuable in thyroid storm when rapid reduction of circulating T3 is critical. Methimazole is the preferred thionamide for most patients because it can be administered once daily (improving adherence), has a more favorable side effect profile, and achieves euthyroidism more reliably. The initial dose of methimazole is typically 10 to 30 mg daily, tapered to a maintenance dose of 5 to 10 mg daily as thyroid function normalizes. PTU requires three-times-daily dosing, with an initial dose of 100 to 200 mg three times daily and a maintenance dose of 50 to 100 mg three times daily.

The side effects of thionamides range from common minor reactions to rare but life-threatening complications. Rash and pruritus are the most common adverse effects and can often be managed with antihistamines or by switching to the alternative thionamide. Gastrointestinal upset is also common and typically managed symptomatically. Agranulocytosis is the most feared complication, occurring in approximately 0.2 to 0.5% of patients; it is potentially fatal if not recognized promptly. All patients must be instructed to report fever or sore throat immediately and to have a white blood cell count checked urgently if these symptoms develop, as agranulocytosis mandates immediate drug discontinuation. Hepatotoxicity occurs rarely but differs between the two agents: PTU causes a hepatocellular pattern that can progress to fulminant liver failure, while methimazole causes a cholestatic pattern that is generally reversible. PTU is also uniquely associated with ANCA-positive vasculitis, which requires drug discontinuation.

Despite methimazole being the preferred agent overall, PTU is specifically indicated in three clinical situations. During the first trimester of pregnancy, PTU is preferred because methimazole is teratogenic, associated with choanal atresia and aplasia cutis. In thyroid storm, PTU's additional ability to block peripheral T4-to-T3 conversion provides a therapeutic advantage. PTU also serves as an alternative when methimazole allergy or intolerance precludes its use, though cross-reactivity between the two thionamides occurs in a minority of cases.

Radioactive iodine (I-131) provides a definitive treatment for hyperthyroidism through targeted destruction of thyroid tissue. I-131 is taken up by thyroid follicular cells via the sodium-iodide symporter, and its beta emission causes local tissue destruction with minimal radiation exposure to surrounding structures. Indications include Graves' disease, toxic nodular goiter, and as adjunctive therapy for differentiated thyroid cancer. The majority of patients treated with radioactive iodine eventually become hypothyroid and require lifelong levothyroxine replacement. Radioactive iodine is absolutely contraindicated in pregnancy and breastfeeding, and women must be counseled to avoid pregnancy for 6 to 12 months after treatment. An important consideration in Graves' disease is that radioactive iodine may worsen Graves' ophthalmopathy, and corticosteroid prophylaxis should be considered in patients with active or significant eye disease. Other antithyroid agents used in specific settings include iodine solutions (Lugol's solution and saturated solution of potassium iodide, or SSKI), which transiently inhibit thyroid hormone release through the Wolff-Chaikoff effect and are used in preoperative preparation for thyroidectomy and in thyroid storm (administered after a thionamide has been given to prevent the iodine from being used as substrate for new hormone synthesis). Lithium blocks thyroid hormone release but is rarely used for this purpose. Perchlorate blocks iodide uptake into the thyroid but is also rarely employed clinically.

<image>Panel A: Thionamide mechanism showing methimazole (preferred, once daily) and propylthiouracil inhibiting TPO to block organification and coupling, with PTU additionally inhibiting peripheral T4 to T3 conversion, and initial versus maintenance dosing for each. Panel B: Thionamide side effects showing common effects (rash, GI upset), rare serious effects (agranulocytosis at 0.2-0.5% requiring WBC check with fever or sore throat, hepatotoxicity, and ANCA vasculitis with PTU). Panel C: PTU-specific indications showing first trimester pregnancy (methimazole is teratogenic causing choanal atresia), thyroid storm (blocks T4 to T3 conversion), and methimazole allergy or intolerance as alternative. Panel D: Radioactive iodine (I-131) and other agents showing I-131 beta emission destroying thyroid tissue for Graves disease, toxic nodular goiter, and thyroid cancer (contraindicated in pregnancy, may worsen ophthalmopathy), plus iodine solutions (Lugol, SSKI) for pre-surgery and thyroid storm use.</image>

III. Glucocorticoid Pharmacology

Glucocorticoids are among the most widely prescribed medications in medicine, with applications spanning virtually every clinical specialty. Their potent anti-inflammatory and immunosuppressive effects make them indispensable for numerous conditions, but their extensive adverse effect profile necessitates careful consideration of dose, duration, and monitoring. Understanding the molecular mechanisms, comparative potencies, and clinical consequences of glucocorticoid therapy is fundamental to safe prescribing.

Glucocorticoids exert their effects primarily through binding to the intracellular glucocorticoid receptor, a nuclear receptor that functions as a ligand-dependent transcription factor. Upon activation, the receptor-ligand complex translocates to the nucleus, where it mediates both transactivation (upregulation of anti-inflammatory genes) and transrepression (downregulation of pro-inflammatory genes). The anti-inflammatory effects are extensive: glucocorticoids decrease the production of cytokines, prostaglandins, and leukotrienes; inhibit phospholipase A2 (via lipocortin induction), thereby reducing arachidonic acid release; and stabilize lysosomal membranes. The immunosuppressive effects include decreased T cell and macrophage function, reduced lymphocyte proliferation, and diminished migration of inflammatory cells to sites of tissue injury.

The various synthetic glucocorticoids differ markedly in their glucocorticoid potency, mineralocorticoid activity, and duration of action, and understanding these differences is critical for selecting the appropriate agent. Hydrocortisone, the synthetic equivalent of endogenous cortisol, serves as the reference with a glucocorticoid potency of 1 and a mineralocorticoid potency of 1, and has a short duration of action. Prednisone has 4 times the glucocorticoid potency and 0.8 times the mineralocorticoid activity of hydrocortisone, with an intermediate duration. Methylprednisolone has a glucocorticoid potency of 5 and a mineralocorticoid potency of 0.5, also with an intermediate duration. Dexamethasone is the most potent at 25 to 30 times the glucocorticoid activity of hydrocortisone, has essentially no mineralocorticoid activity (potency of 0), and has a long duration of action, making it useful when prolonged suppression without sodium retention is desired. Fludrocortisone has moderate glucocorticoid potency (10) but extremely high mineralocorticoid potency (125), and is used primarily as a mineralocorticoid replacement rather than as an anti-inflammatory agent. The equivalent dose conversions are clinically important: 20 mg of hydrocortisone is equivalent to 5 mg of prednisone, which is equivalent to 0.75 mg of dexamethasone.

The therapeutic applications of glucocorticoids are extraordinarily diverse. In endocrinology, they serve as replacement therapy for adrenal insufficiency. In inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, and asthma, they provide rapid suppression of the inflammatory cascade. Autoimmune conditions including systemic lupus erythematosus and vasculitis frequently require glucocorticoid therapy. Severe allergic reactions such as anaphylaxis and angioedema are treated with glucocorticoids as adjunctive therapy. Transplant immunosuppression protocols routinely include glucocorticoids. In oncology, glucocorticoids are used in lymphoma treatment regimens and for management of tumor-associated cerebral edema.

The adverse effects of chronic glucocorticoid therapy are extensive and affect virtually every organ system. Metabolic effects include hyperglycemia (steroid-induced diabetes), weight gain, and fat redistribution producing the characteristic Cushingoid appearance with central obesity, moon facies, and dorsocervical fat pad. Skeletal effects include osteoporosis (the most common cause of drug-induced osteoporosis) and osteonecrosis, particularly of the femoral head. Cardiovascular effects include hypertension and dyslipidemia. Immunosuppression increases susceptibility to opportunistic infections. Gastrointestinal complications include peptic ulcer disease, particularly when glucocorticoids are co-administered with NSAIDs. Dermatologic effects include thin, fragile skin, striae, easy bruising, and impaired wound healing. Ocular complications include posterior subcapsular cataracts and increased intraocular pressure (glaucoma). Psychiatric effects range from mood changes, insomnia, and euphoria to frank psychosis. Endocrine consequences include suppression of the hypothalamic-pituitary-adrenal (HPA) axis and growth suppression in children.

HPA axis suppression is a critically important consequence of chronic glucocorticoid therapy. The risk is low with courses shorter than 3 weeks, but increases substantially with longer duration and higher doses of supraphysiologic glucocorticoid therapy. After discontinuation of prolonged glucocorticoid therapy, recovery of the HPA axis may take months, during which the patient remains at risk for adrenal crisis if exposed to physiologic stress. This is why gradual tapering is required when discontinuing glucocorticoids after prolonged use: abrupt cessation can precipitate acute adrenal insufficiency. During the recovery period, stress dosing with supplemental glucocorticoids may be necessary during acute illness, surgery, or other significant physiologic stressors to compensate for the adrenal glands' inability to mount an appropriate cortisol response.

<image>Panel A: Glucocorticoid mechanism showing intracellular receptor binding, genomic transactivation and transrepression of genes, anti-inflammatory effects (decreased cytokines, prostaglandins, leukotrienes), and immunosuppressive effects (decreased T cell and macrophage function). Panel B: Comparative potency table showing hydrocortisone (glucocorticoid 1, mineralocorticoid 1, short), prednisone (4, 0.8, intermediate), methylprednisolone (5, 0.5, intermediate), dexamethasone (25-30, 0, long), and fludrocortisone (10, 125, intermediate) with equivalent dose conversions. Panel C: Adverse effects by system showing metabolic (hyperglycemia, weight gain), skeletal (osteoporosis, osteonecrosis), cardiovascular (hypertension), immune (infection risk), GI (peptic ulcer with NSAIDs), dermatologic (thin skin, striae), ocular (cataracts, glaucoma), and psychiatric (mood changes). Panel D: HPA axis suppression showing low risk with less than 3 weeks of use, increasing risk with prolonged supraphysiologic doses, recovery potentially taking months, requirement for gradual tapering, and stress dosing needs during illness or surgery.</image>

IV. Mineralocorticoid Pharmacology

Mineralocorticoid pharmacology encompasses both agonists used for replacement therapy and antagonists used to treat conditions of mineralocorticoid excess or to exploit the therapeutic benefits of aldosterone blockade. The mineralocorticoid receptor plays a central role in sodium and potassium homeostasis, blood pressure regulation, and, as increasingly recognized, cardiac and renal fibrosis, making this pharmacologic axis relevant to endocrinology, cardiology, and nephrology alike.

Fludrocortisone is the primary mineralocorticoid receptor agonist used in clinical practice. Its principal indication is as replacement therapy in primary adrenal insufficiency (Addison's disease), where it replaces the aldosterone that the destroyed adrenal cortex can no longer produce. Fludrocortisone is also used to treat orthostatic hypotension when non-pharmacologic measures are insufficient. As a potent mineralocorticoid receptor agonist, fludrocortisone promotes sodium retention and potassium excretion in the renal collecting duct, thereby expanding intravascular volume and raising blood pressure. The typical dose ranges from 0.05 to 0.2 mg daily. Monitoring should include regular assessment of blood pressure, peripheral edema, and serum potassium levels, as excessive dosing can lead to hypertension, edema, and hypokalemia.

Mineralocorticoid receptor antagonists represent a pharmacologically important class with expanding clinical applications. Spironolactone is a non-selective antagonist that blocks the mineralocorticoid receptor but also has significant anti-androgen activity due to its structural similarity to sex steroids. This dual activity accounts for both its therapeutic utility in conditions such as polycystic ovary syndrome (PCOS) and its characteristic side effects. Spironolactone is widely used in heart failure with reduced ejection fraction (where it reduces mortality), resistant hypertension, ascites from cirrhosis, and primary aldosteronism (bilateral adrenal hyperplasia). Eplerenone is a selective mineralocorticoid receptor antagonist with minimal anti-androgen effects, making it better tolerated in terms of sexual side effects. It is primarily indicated for heart failure and hypertension. Finerenone is a novel non-steroidal, selective mineralocorticoid receptor antagonist that has demonstrated significant renal and cardiovascular benefits in patients with chronic kidney disease and type 2 diabetes, representing an important addition to the management of diabetic kidney disease.

The side effects of spironolactone relate directly to its pharmacologic profile. Hyperkalemia is the most clinically significant adverse effect, resulting from decreased renal potassium excretion, and requires monitoring of serum potassium levels, particularly in patients with renal impairment or those taking other potassium-elevating medications. Gynecomastia and breast tenderness in men, along with menstrual irregularities in women, are common anti-androgen side effects that are dose-dependent and reversible upon drug discontinuation. Gastrointestinal upset is also common. Eplerenone causes less gynecomastia than spironolactone due to its greater selectivity for the mineralocorticoid receptor, which makes it a preferred alternative when anti-androgen side effects are problematic.

<image>Panel A: Fludrocortisone as mineralocorticoid receptor agonist showing indications (primary adrenal insufficiency, orthostatic hypotension), dose of 0.05-0.2 mg daily, effects (sodium retention, potassium excretion, volume expansion), and monitoring (blood pressure, edema, potassium). Panel B: Mineralocorticoid receptor antagonists comparison showing spironolactone (non-selective with anti-androgen effects, used for heart failure, hypertension, ascites, PCOS), eplerenone (selective with fewer anti-androgen effects, for heart failure and hypertension), and finerenone (non-steroidal selective, for CKD in type 2 diabetes). Panel C: Spironolactone side effects showing hyperkalemia (decreased potassium excretion), gynecomastia (anti-androgen effect), menstrual irregularities, and GI upset, with eplerenone noted as having less gynecomastia due to greater selectivity. Panel D: Clinical applications showing spironolactone for primary aldosteronism (bilateral hyperplasia), heart failure with reduced ejection fraction, resistant hypertension, and ascites in cirrhosis, with potassium monitoring as essential safety measure.</image>

V. Drugs Affecting Calcium and Bone

Pharmacotherapy for disorders of calcium and bone metabolism encompasses antiresorptive agents that reduce bone breakdown, anabolic agents that stimulate new bone formation, calcium and vitamin D supplementation, and calcimimetics that modulate parathyroid hormone secretion. These agents are used in the treatment of osteoporosis, hypercalcemia, hypoparathyroidism, Paget disease of bone, and secondary hyperparathyroidism of chronic kidney disease.

Bisphosphonates are the most widely used antiresorptive agents and remain the first-line pharmacologic therapy for osteoporosis. They bind to hydroxyapatite in bone and are preferentially taken up by osteoclasts during bone resorption. Once internalized, bisphosphonates inhibit osteoclast function and promote osteoclast apoptosis, thereby reducing bone resorption and increasing bone mineral density. Available oral agents include alendronate and risedronate, while zoledronic acid is administered intravenously. Beyond osteoporosis, bisphosphonates are used to treat hypercalcemia of malignancy and Paget disease of bone. Oral bisphosphonates must be taken on an empty stomach with a full glass of water, and the patient must remain upright for at least 30 minutes to minimize the risk of esophageal erosion. The adverse effects of bisphosphonates are important to recognize. Gastrointestinal effects, including esophagitis and esophageal ulceration, are the most common side effects of oral formulations. Osteonecrosis of the jaw is a rare but serious complication that is more frequent with intravenous bisphosphonates and in patients undergoing dental procedures. Atypical femoral fractures (subtrochanteric or diaphyseal) have been associated with prolonged bisphosphonate use, prompting consideration of drug holidays after 3 to 5 years of therapy in appropriate patients. Acute phase reactions with flu-like symptoms (fever, myalgias, arthralgias) are common after intravenous administration. Hypocalcemia can occur, particularly in patients with pre-existing renal impairment or vitamin D deficiency.

Denosumab is a monoclonal antibody directed against RANKL (receptor activator of nuclear factor kappa-B ligand), the key cytokine that stimulates osteoclast differentiation and activation. By binding and neutralizing RANKL, denosumab potently inhibits osteoclast-mediated bone resorption. It is administered as 60 mg subcutaneously every 6 months for osteoporosis treatment. An important consideration with denosumab is the risk of rebound bone loss if the drug is discontinued: rapid increases in bone resorption and associated vertebral fractures have been reported after stopping denosumab, necessitating transition to an alternative antiresorptive agent (typically a bisphosphonate) when denosumab is discontinued. Hypocalcemia is another important adverse effect.

PTH analogs represent the anabolic approach to osteoporosis treatment, directly stimulating new bone formation rather than merely slowing bone loss. Teriparatide, a recombinant fragment of parathyroid hormone comprising amino acids 1 through 34 (PTH 1-34), is administered as a daily subcutaneous injection and stimulates osteoblast activity and new bone formation when given intermittently (as opposed to the continuous PTH elevation of hyperparathyroidism, which favors resorption). Abaloparatide is a PTHrP (parathyroid hormone-related peptide) analog with a similar mechanism and clinical use. Both agents are indicated for severe osteoporosis in patients at high fracture risk, including those who have failed or cannot tolerate bisphosphonate therapy. Treatment duration is limited to a maximum of 2 years, based on a preclinical finding of osteosarcoma in rats treated with prolonged high-dose teriparatide, though this risk has not been demonstrated in humans. After completion of an anabolic course, patients are typically transitioned to an antiresorptive agent to maintain the gains in bone density.

Calcium and vitamin D are foundational elements of bone health. Calcium carbonate is the most commonly used calcium supplement; it requires gastric acid for absorption and should be taken with food. Calcium citrate does not require acid for absorption and can be taken on an empty stomach, making it a better option for patients on proton pump inhibitors or with achlorhydria. Vitamin D supplementation, available as ergocalciferol (D2) or cholecalciferol (D3), is indicated for deficiency states and is co-administered with calcium for osteoporosis prevention and treatment. Calcitriol (1,25-dihydroxyvitamin D), the active form of vitamin D, bypasses the renal hydroxylation step and is specifically indicated for hypoparathyroidism (where the absence of PTH impairs renal 1-alpha-hydroxylation) and for chronic kidney disease (where impaired renal function reduces calcitriol production). Cinacalcet is a calcimimetic that acts as an allosteric agonist of the calcium-sensing receptor (CaSR) on parathyroid chief cells, making the receptor more sensitive to extracellular calcium and thereby suppressing PTH secretion. It is indicated for secondary hyperparathyroidism in chronic kidney disease, primary hyperparathyroidism in patients who are not surgical candidates, and parathyroid carcinoma. The main side effects of cinacalcet are hypocalcemia and nausea.

<image>Panel A: Bisphosphonate mechanism showing inhibition of osteoclast function and promotion of osteoclast apoptosis, with oral agents (alendronate, risedronate requiring empty stomach and upright positioning) and IV agent (zoledronic acid), indicated for osteoporosis, hypercalcemia of malignancy, and Paget disease. Panel B: Bisphosphonate adverse effects showing GI effects (esophagitis, ulceration with oral forms), osteonecrosis of the jaw (rare, higher with IV and dental procedures), atypical femur fractures (prolonged use), acute phase reaction (flu-like with IV), and hypocalcemia. Panel C: Denosumab versus teriparatide comparison showing denosumab as RANKL monoclonal antibody inhibiting osteoclast activation (antiresorptive, 60 mg SQ every 6 months with rebound bone loss risk if stopped) versus teriparatide as PTH 1-34 analog stimulating bone formation (anabolic, daily SQ for maximum 2 years). Panel D: Calcium, vitamin D, and calcimimetics showing calcium carbonate (requires acid, take with food) versus calcium citrate (no acid needed), vitamin D supplementation, calcitriol for hypoparathyroidism and CKD, and cinacalcet as CaSR agonist decreasing PTH for secondary HPT and parathyroid carcinoma.</image>

VI. Pituitary Pharmacology

The pituitary gland serves as the master regulator of the endocrine system, and pharmacologic agents targeting pituitary hormones and their receptors are essential for managing conditions of hormone excess and deficiency. These agents include recombinant hormones for replacement therapy, receptor antagonists and analogs for states of hormone excess, and drugs that modulate pituitary secretion through dopaminergic and somatostatinergic pathways.

Growth hormone pharmacology centers on recombinant human growth hormone (somatropin) for replacement and several agents for suppression of GH excess. Somatropin is indicated for growth hormone deficiency in both pediatric and adult patients, as well as for Turner syndrome and other conditions associated with short stature. Side effects of somatropin therapy include peripheral edema, arthralgias, carpal tunnel syndrome, and glucose intolerance, reflecting the metabolic effects of GH. Somatropin is contraindicated in patients with active malignancy and proliferative diabetic retinopathy, as GH and its downstream mediator IGF-1 can promote cell proliferation. For acromegaly, pegvisomant is a GH receptor antagonist that blocks the action of GH at the receptor level, effectively normalizing IGF-1 levels without reducing GH secretion itself. Somatostatin analogs, which suppress GH secretion from the anterior pituitary, represent the other major pharmacologic approach to acromegaly.

Somatostatin analogs are synthetic peptides that mimic the inhibitory effects of native somatostatin but with longer half-lives suitable for clinical use. Octreotide is available in both a short-acting subcutaneous formulation and a long-acting depot preparation administered monthly. Lanreotide is available as a long-acting depot injection. Beyond acromegaly, somatostatin analogs have important applications in the management of carcinoid syndrome (suppressing serotonin and other hormone secretion), VIPoma (reducing vatery diarrhea), and esophageal variceal bleeding (reducing splanchnic blood flow). Side effects include gastrointestinal symptoms such as diarrhea, cholelithiasis (gallstone formation from impaired gallbladder motility), bradycardia, and effects on glucose metabolism (both hyperglycemia and hypoglycemia can occur, as somatostatin inhibits both insulin and glucagon secretion).

Dopamine agonists are the first-line treatment for prolactinomas, exploiting the fact that dopamine is the primary physiologic inhibitor of prolactin secretion. Cabergoline, a long-acting D2 receptor agonist administered twice weekly, is the preferred agent due to its superior efficacy, better side effect profile, and more convenient dosing schedule. Bromocriptine, an older D2 agonist requiring daily dosing, is an alternative but causes more frequent side effects. Both agents effectively reduce prolactin levels and, importantly, shrink prolactinoma tumor size, making medical therapy rather than surgery the first-line approach for most prolactinomas. Side effects of dopamine agonists include nausea, orthostatic hypotension, impulse control disorders, and, at high doses (primarily with cabergoline in Parkinson's disease), valvular heart disease—though this is not a significant concern at the doses used for prolactinoma treatment.

ADH (antidiuretic hormone) pharmacology addresses both deficiency and excess states. Desmopressin (DDAVP) is a synthetic analog of vasopressin that selectively activates V2 receptors in the renal collecting duct, promoting water reabsorption. It is the primary treatment for central diabetes insipidus, where endogenous ADH production is deficient. Desmopressin also has non-renal applications, including treatment of von Willebrand disease (it stimulates release of von Willebrand factor and factor VIII from endothelial stores) and nocturnal enuresis. In contrast, the vaptans—tolvaptan and conivaptan—are V2 receptor antagonists that block the action of ADH and are used to treat hyponatremia, particularly that caused by SIADH (syndrome of inappropriate antidiuretic hormone secretion). Vaptans produce aquaresis—the excretion of free water without significant sodium loss—thereby raising the serum sodium concentration.

<image>Panel A: Growth hormone pharmacology showing somatropin (recombinant GH) for GH deficiency and Turner syndrome with side effects (edema, arthralgias, glucose intolerance), and GH antagonist pegvisomant for acromegaly. Panel B: Somatostatin analogs showing octreotide and lanreotide decreasing GH secretion for acromegaly, carcinoid, and VIPoma, with side effects of diarrhea, cholelithiasis, bradycardia, and glucose effects. Panel C: Dopamine agonists showing cabergoline (preferred D2 agonist, twice weekly) and bromocriptine for prolactinoma as first-line treatment achieving tumor shrinkage and prolactin reduction, with side effects of nausea, orthostatic hypotension, and valvulopathy risk at high doses. Panel D: ADH pharmacology showing desmopressin (DDAVP) as V2 receptor agonist for central diabetes insipidus, von Willebrand disease, and nocturnal enuresis, versus vaptans (tolvaptan, conivaptan) as V2 antagonists for SIADH and hyponatremia causing aquaresis without sodium loss.</image>

VII. Diabetes Pharmacology Summary

Diabetes pharmacology encompasses an extensive array of agents that target different aspects of glucose homeostasis. A comprehensive understanding of insulin pharmacokinetics and the mechanisms of non-insulin agents is essential for rational prescribing, and reviewing these drug classes together highlights the complementary approaches available for individualized therapy.

The insulin pharmacokinetic profiles determine how each formulation is used clinically. Rapid-acting insulins (lispro and aspart) have the fastest onset at 10 to 15 minutes, peak at 1 to 2 hours, and last 3 to 5 hours, making them ideal for prandial coverage and correction dosing. Short-acting regular insulin has a somewhat delayed onset of 30 to 60 minutes, peaks at 2 to 4 hours, and has a duration of 5 to 8 hours; it is used in intravenous infusions (the only insulin suitable for IV administration) and occasionally for mealtime dosing. Intermediate-acting NPH insulin has an onset of 1 to 2 hours, a pronounced peak at 4 to 10 hours, and a duration of 12 to 18 hours, providing intermediate-duration basal coverage but with a peak that predisposes to hypoglycemia. Long-acting glargine and detemir have an onset of 1 to 2 hours, provide a flat profile without significant peaks, and last 20 to 24 hours, making them the preferred basal insulins for most patients. Ultra-long-acting degludec extends the duration beyond 42 hours with a flat profile, offering even more stable basal coverage and the flexibility of varying injection times.

The non-insulin agents for type 2 diabetes each target distinct pathophysiologic mechanisms. Metformin, the first-line agent, decreases hepatic glucose production and is valued for being inexpensive, weight neutral, and free of hypoglycemia risk, though gastrointestinal side effects and the rare risk of lactic acidosis are concerns. Sulfonylureas increase insulin secretion by closing ATP-sensitive potassium channels on beta cells; they are effective and inexpensive but carry risks of hypoglycemia and weight gain. SGLT2 inhibitors decrease renal glucose reabsorption, providing the important benefits of cardiovascular and renal protection along with weight loss, but increase the risk of urinary tract infections and euglycemic DKA. GLP-1 receptor agonists function as incretin mimetics, offering substantial weight loss and cardiovascular protection, though gastrointestinal side effects and the rare risk of pancreatitis must be considered. DPP-4 inhibitors increase endogenous incretin levels and are well tolerated with no hypoglycemia risk, but their glucose-lowering efficacy is modest. TZDs activate PPARgamma to improve insulin sensitivity, providing durable glucose lowering, but are limited by weight gain, heart failure risk, and fractures.

<image>Panel A: Insulin types review table showing rapid-acting (lispro, aspart; 10-15 min onset, 3-5 hr duration), short (regular; 30-60 min, 5-8 hr), intermediate (NPH; 1-2 hr onset, 12-18 hr), long-acting (glargine, detemir; flat profile, 20-24 hr), and ultra-long (degludec; greater than 42 hr). Panel B: Non-insulin oral agents summary showing metformin (decreased hepatic glucose, first-line, cheap), sulfonylureas (increased insulin secretion, cheap but hypoglycemia), SGLT2i (decreased renal reabsorption, CV/renal protection, weight loss), and DPP-4i (increased incretins, well tolerated, modest efficacy). Panel C: Injectable and additional oral agents showing GLP-1 RA (incretin mimetic, weight loss, CV protection, GI side effects), TZDs (PPARgamma agonist, durable insulin sensitizer but weight gain, heart failure, fractures), and alpha-glucosidase inhibitors. Panel D: Agent selection framework organized by mechanism of action showing insulin secretagogues (sulfonylureas, meglitinides), insulin sensitizers (metformin, TZDs), incretin-based (GLP-1 RA, DPP-4i), and glucose excretion (SGLT2i) with key benefit and risk for each class.</image>

VIII. Reproductive Endocrine Pharmacology

Reproductive endocrine pharmacology encompasses a broad range of agents that modulate the hypothalamic-pituitary-gonadal axis, including sex steroids for replacement and contraception, selective estrogen receptor modulators with tissue-specific effects, aromatase inhibitors for breast cancer, androgens and anti-androgens, and GnRH analogs that can either stimulate or suppress gonadotropin secretion depending on their mode of administration.

Estrogens and progestins form the foundation of reproductive pharmacology. Estrogen preparations include natural estradiol used for hormone replacement therapy (HRT) and hypogonadism, conjugated equine estrogens (Premarin) also used for HRT, and synthetic ethinyl estradiol used in oral contraceptive formulations. Progestins include natural micronized progesterone used for HRT and luteal phase support in assisted reproduction, as well as synthetic progestins such as medroxyprogesterone and norethindrone used in contraception and for the treatment of endometriosis. Progestins are essential in HRT for women with an intact uterus, as they protect against the endometrial hyperplasia and cancer that can result from unopposed estrogen stimulation.

Selective estrogen receptor modulators (SERMs) are a fascinating class of drugs that exhibit tissue-specific agonist or antagonist activity at estrogen receptors. Tamoxifen acts as an antagonist in breast tissue (making it a cornerstone of estrogen receptor-positive breast cancer treatment) but as an agonist in the uterus (increasing the risk of endometrial hyperplasia and cancer) and in bone (providing protective effects against osteoporosis). Raloxifene acts as an antagonist in breast tissue and as an agonist in bone, but without the uterine stimulatory effects of tamoxifen, making it useful for both osteoporosis treatment and breast cancer prevention. Clomiphene acts as an estrogen antagonist at the hypothalamus, blocking the negative feedback of estrogen and thereby increasing gonadotropin (FSH and LH) release, which stimulates ovarian follicle development—this is the basis for its use in ovulation induction for infertility treatment.

Aromatase inhibitors, including anastrozole and letrozole, block the aromatase enzyme that converts androgens to estrogens in peripheral tissues. They are a mainstay of treatment for estrogen receptor-positive breast cancer in postmenopausal women (in whom peripheral aromatization is the primary source of estrogen, as ovarian function has ceased). Side effects include hot flashes, arthralgias, and accelerated osteoporosis from estrogen deprivation.

Androgens and anti-androgens address disorders of androgen excess and deficiency. Testosterone replacement is the treatment for male hypogonadism, available in various formulations including injections, transdermal patches, and gels. Anti-androgens serve different clinical needs: spironolactone blocks the androgen receptor and is used for the hirsutism and acne of PCOS; finasteride and dutasteride are 5-alpha-reductase inhibitors that block the conversion of testosterone to the more potent dihydrotestosterone (DHT), used for benign prostatic hyperplasia (BPH) and male pattern baldness; and flutamide is a direct androgen receptor antagonist used in prostate cancer treatment.

GnRH analogs demonstrate a remarkable pharmacologic principle in which the same molecule can produce opposite effects depending on the pattern of administration. When GnRH agonists such as leuprolide are given in a pulsatile fashion (mimicking the normal physiologic pattern of hypothalamic GnRH release), they stimulate gonadotropin secretion and can be used to treat infertility. However, when given continuously (as in depot preparations), GnRH agonists initially cause a transient surge in gonadotropins (the "flare" effect) followed by profound downregulation of GnRH receptors, leading to suppression of gonadotropin secretion and subsequent reduction in sex steroid production. This continuous administration is exploited therapeutically in prostate cancer, endometriosis, uterine fibroids, and central precocious puberty. GnRH antagonists such as degarelix bypass the initial flare and produce immediate suppression of gonadotropins, making them useful in prostate cancer (where an initial testosterone flare could worsen symptoms) and in IVF protocols.

<image>Panel A: Estrogen and progestin options showing estrogens (estradiol for HRT, conjugated premarin for HRT, ethinyl estradiol for contraception) and progestins (progesterone for HRT and luteal support, medroxyprogesterone and norethindrone for contraception and endometriosis). Panel B: Selective estrogen receptor modulators showing tissue-specific effects with tamoxifen (antagonist in breast but agonist in uterus and bone for breast cancer), raloxifene (antagonist in breast, agonist in bone for osteoporosis), and clomiphene (antagonist in hypothalamus increasing gonadotropins for ovulation induction). Panel C: Aromatase inhibitors and androgens showing anastrozole and letrozole blocking estrogen synthesis for postmenopausal breast cancer (with hot flashes and osteoporosis), testosterone for male hypogonadism, and anti-androgens (spironolactone, finasteride, flutamide) for PCOS and BPH. Panel D: GnRH analogs showing pulsatile agonists stimulating gonadotropins (for infertility), continuous agonists downregulating and suppressing (leuprolide for prostate cancer, endometriosis, precocious puberty), and antagonists providing immediate suppression (degarelix for prostate cancer and IVF).</image>

IX. Other Endocrine Agents

Several endocrine agents target specific disease states that do not fit neatly into the major categories discussed previously. These include drugs for hyperprolactinemia, Cushing syndrome, pheochromocytoma, and acromegaly—conditions where pharmacologic therapy may serve as primary treatment, as a bridge to definitive surgery, or for patients who are not surgical candidates.

The pharmacologic treatment of hyperprolactinemia relies on dopamine agonists, which exploit the physiologic inhibition of prolactin secretion by dopamine. Cabergoline is the preferred agent, administered as a D2 receptor agonist given twice weekly. It achieves normalization of prolactin levels in the vast majority of patients and produces significant tumor shrinkage in prolactinomas, making it the first-line therapy over surgery for most patients with this condition. Bromocriptine, the original dopamine agonist used for this indication, requires daily dosing and is associated with more frequent side effects (nausea, orthostatic hypotension, headache), making it a second-line option. The response to dopamine agonist therapy includes both reduction in prolactin levels and reduction in tumor mass, which can be monitored by serial MRI imaging.

Cushing syndrome—the clinical manifestation of chronic glucocorticoid excess—can be treated with several pharmacologic agents when surgery is not feasible or has not achieved remission. Ketoconazole is a broad-spectrum steroidogenesis inhibitor that blocks multiple enzymes in the cortisol synthetic pathway and serves as a commonly used medical therapy. Metyrapone is a selective inhibitor of 11-beta-hydroxylase, the enzyme catalyzing the final step in cortisol synthesis, and is used for cortisol reduction. Osilodrostat is a newer and more potent 11-beta-hydroxylase inhibitor that has been specifically approved for Cushing disease. Mifepristone is a glucocorticoid receptor antagonist that blocks the action of cortisol at its receptor rather than reducing cortisol production; it is used for the hyperglycemia associated with Cushing syndrome. Pasireotide is a somatostatin analog that acts on somatostatin receptor subtype 5 (which is highly expressed on corticotroph adenomas) and is indicated for Cushing disease when pituitary surgery has failed.

The pharmacologic management of pheochromocytoma focuses on alpha-adrenergic blockade for preoperative preparation and acute crisis management. Phenoxybenzamine is an irreversible, non-selective alpha-adrenergic blocker used as the standard preoperative preparation agent, administered for 10 to 14 days before surgery to control blood pressure and allow volume expansion. Phentolamine is a reversible alpha-blocker used for the acute management of hypertensive crises during pheochromocytoma. Metyrosine (alpha-methyltyrosine) inhibits tyrosine hydroxylase, the rate-limiting enzyme in catecholamine synthesis, and is used as an adjunct to reduce catecholamine production when alpha-blockade alone is insufficient.

Acromegaly, caused by excess growth hormone secretion, is treated pharmacologically when surgery does not achieve biochemical remission. Somatostatin analogs—octreotide and lanreotide—are the most commonly used medical therapies, suppressing GH secretion and normalizing IGF-1 levels in approximately 50 to 60% of patients. Pegvisomant, a GH receptor antagonist, is the most effective agent for normalizing IGF-1 levels but does not reduce tumor size (since it blocks GH action rather than GH secretion). Cabergoline, used as a dopamine agonist, has a modest effect on GH suppression in acromegaly and is sometimes used as adjunctive therapy, particularly in tumors that co-secrete prolactin.

<image>Panel A: Drugs for hyperprolactinemia showing cabergoline (preferred D2 agonist, twice weekly) and bromocriptine (daily, more side effects) achieving tumor shrinkage and prolactin reduction as medical first-line therapy. Panel B: Drugs for Cushing syndrome showing steroidogenesis inhibitors (ketoconazole, metyrapone, osilodrostat), glucocorticoid receptor antagonist (mifepristone), somatostatin analog (pasireotide for Cushing disease), and adrenolytic agent (mitotane). Panel C: Drugs for pheochromocytoma showing phenoxybenzamine (irreversible alpha-blocker for preoperative preparation), phentolamine (reversible alpha-blocker for hypertensive crisis), and metyrosine (tyrosine hydroxylase inhibitor decreasing catecholamine synthesis). Panel D: Drugs for acromegaly showing somatostatin analogs (octreotide and lanreotide decreasing GH secretion), pegvisomant (GH receptor antagonist), and cabergoline (dopamine agonist with mild effect) as options when surgery is incomplete or not feasible.</image>

X. Drug Interactions in Endocrine Therapy

Drug interactions are a pervasive concern in endocrine pharmacotherapy, as many endocrine agents have narrow therapeutic windows, are affected by changes in absorption or metabolism, and are used in patients on complex multi-drug regimens. Systematic awareness of these interactions and the principles governing them is essential for avoiding adverse outcomes.

Thyroid hormone interactions are among the most commonly encountered in endocrine practice. Calcium supplements, iron preparations, and aluminum-containing antacids bind levothyroxine in the gastrointestinal tract, significantly reducing its absorption and necessitating a separation of at least 4 hours between these agents and levothyroxine dosing. Hepatic enzyme inducers such as phenytoin and carbamazepine increase the metabolism of T4, potentially requiring levothyroxine dose increases in patients on these anticonvulsants. Estrogen and pregnancy increase thyroxine-binding globulin (TBG) production, which raises total T4 levels and may necessitate dose adjustment to maintain normal free T4 and TSH. Amiodarone has complex and multifaceted effects on thyroid function: it is rich in iodine (each 200 mg tablet contains approximately 75 mg of organic iodine) and can cause both hypothyroidism (via the Wolff-Chaikoff effect, particularly in patients with underlying autoimmune thyroid disease) and hyperthyroidism (via either iodine-induced thyrotoxicosis or a destructive thyroiditis), requiring regular thyroid function monitoring in all patients on amiodarone.

Glucocorticoid interactions center largely on hepatic cytochrome P450 3A4 (CYP3A4) metabolism. Potent CYP3A4 inducers such as rifampin markedly increase glucocorticoid metabolism, reducing their therapeutic effect and potentially precipitating adrenal crisis in patients on replacement doses. Conversely, CYP3A4 inhibitors (such as ketoconazole, itraconazole, and ritonavir) decrease glucocorticoid metabolism, increasing their effective potency and risk of adverse effects. The co-administration of glucocorticoids with NSAIDs substantially increases the risk of peptic ulcer disease, as both agents impair the protective prostaglandin-mediated gastric mucosal barrier. The combination of glucocorticoids with fluoroquinolone antibiotics increases the risk of tendon rupture, a particularly important interaction in elderly patients.

Diabetes drug interactions can have potentially dangerous consequences for glycemic control. Beta-blockers mask the autonomic (adrenergic) symptoms of hypoglycemia—tremor, palpitations, and tachycardia—potentially causing patients to miss the early warning signs of low blood sugar and progress to severe neuroglycopenic hypoglycemia. Fluoroquinolone antibiotics can cause both hypoglycemia and hyperglycemia, particularly when co-administered with sulfonylureas, through mechanisms that are not fully understood. ACE inhibitors may increase the risk of hypoglycemia when used with sulfonylureas, possibly by improving insulin sensitivity. Alcohol increases the risk of hypoglycemia by inhibiting hepatic gluconeogenesis and also increases the risk of metformin-associated lactic acidosis.

The general principles governing drug interactions in endocrine therapy should guide clinical practice. Close monitoring of relevant laboratory parameters (TSH, glucose, cortisol, electrolytes) is essential when starting or stopping medications that may interact with endocrine therapies. Patient education is critical, as many over-the-counter medications and dietary supplements can interact with endocrine drugs—for example, calcium and iron supplements with levothyroxine, or herbal products affecting cytochrome P450 enzymes. Renal function should be assessed regularly, as many endocrine agents (particularly metformin, certain sulfonylureas, and their metabolites) require dose adjustment in renal impairment. Finally, awareness of drug-disease interactions is important: for example, glucocorticoids should be used with caution in diabetes (worsening hyperglycemia), TZDs are contraindicated in heart failure, and metformin must be held in conditions predisposing to lactic acidosis.

<image>Panel A: Thyroid hormone interactions showing calcium, iron, and antacids decreasing T4 absorption, phenytoin and carbamazepine increasing T4 metabolism, estrogen and pregnancy increasing TBG (increasing total T4), and amiodarone causing multiple thyroid effects (hypo or hyperthyroidism). Panel B: Glucocorticoid interactions showing CYP3A4 inducers (rifampin) increasing steroid metabolism and decreasing effect, CYP3A4 inhibitors decreasing metabolism and increasing effect, NSAIDs increasing GI ulcer risk, and fluoroquinolones increasing tendon rupture risk. Panel C: Diabetes drug interactions showing beta-blockers masking hypoglycemia symptoms, fluoroquinolones causing glucose dysregulation with sulfonylureas, ACE inhibitors increasing hypoglycemia risk with sulfonylureas, and alcohol increasing hypoglycemia and metformin lactic acidosis risk. Panel D: General pharmacologic principles showing close monitoring when starting or stopping interacting drugs, patient education about OTC drugs and supplement interactions, renal function assessment for dose adjustment, and drug-disease contraindication awareness.</image>

Summary

• Thyroid: Levothyroxine (T4) is standard replacement; thionamides block synthesis
• Glucocorticoids: Anti-inflammatory/immunosuppressive; many adverse effects; taper after prolonged use
• Mineralocorticoids: Fludrocortisone for replacement; spironolactone/eplerenone antagonists
• Bone agents: Bisphosphonates and denosumab are antiresorptive; teriparatide is anabolic
• Pituitary: GH, somatostatin analogs, dopamine agonists, desmopressin/vaptans
• Diabetes: Insulin types by onset/duration; oral agents by mechanism and comorbidity benefits
• Reproductive: Estrogens, progestins, SERMs, aromatase inhibitors, GnRH analogs

Key Terms

This content is subject to the MIT License. © 2024–2026 Hibbert School of Medicine.

Read this lecture as Markdown